« Back
Home /
Rociletinib hydrobromide

Rociletinib hydrobromide

Item no.	HY-15729A-10mg
Manufacturer	MedChem Express
CASRN	1446700-26-0
Amount	10 mg
Quantity options	100 mg 10 mM/1 mL 10 mg 50 mg 5 mg
Category	Oncology Neuroscience Neural Signaling Inhibitors & Compound Libraries Small Molecules By Organ Lung Cancer Bladder Cancer
Type	Inhibitors
Specific against	other
Purity	98.04
Citations	[1]Walter AO, et al. Discovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC. Cancer Discov. 2013 Sep 25.
Smiles	C=CC(NC1=CC=CC(NC2=NC(NC3=CC=C(N4CCN(C(C)=O)CC4)C=C3OC)=NC=C2C(F)(F)F)=C1)=O.[H]Br
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	CO-1686 (hydrobromide),AVL-301 hydrobromide,CNX-419 hydrobromide
Shipping Condition	Room temperature
Available
Manufacturer - Type	Reference compound
Manufacturer - Applications	Cancer-Kinase/protease
Manufacturer - Targets	EGFR
Shipping Temperature	Room Temperature
Storage Conditions	4°C (Powder, sealed storage, away from moisture)
Molecular Weight	636.46
Product Description	Rociletinib hydrobromide (CO-1686 hydrobromide) is an orally delivered kinase inhibitor that specifically targets the mutant forms of EGFR including T790M, and the Ki values for EGFRL858R/T790M and EGFRWT are 21.5 nM and 303.3 nM, respectively.
Manufacturer - Research Area	Cancer
Solubility	DMSO: ≥ 59 mg/mL\|H2O: < 0.1 mg/mL
Manufacturer - Pathway	JAK/STAT Signaling; Protein Tyrosine Kinase/RTK
Isoform	EGFR/ErbB1/HER1
Clinical information	Phase 3

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

HY-15729A-10mg-safety-datasheet.pdf